Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Liabilities: 2022-2025

Historic Other Non-Current Liabilities for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • Taysha Gene Therapies' Other Non-Current Liabilities fell 96.45% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 96.45%. This contributed to the annual value of $1.3 million for FY2024, which is 16.99% down from last year.
  • Taysha Gene Therapies' Other Non-Current Liabilities amounted to $1.6 million in Q3 2025, which was up 12.89% from $1.4 million recorded in Q2 2025.
  • Taysha Gene Therapies' Other Non-Current Liabilities' 5-year high stood at $44.4 million during Q3 2024, with a 5-year trough of $1.2 million in Q1 2025.
  • Its 3-year average for Other Non-Current Liabilities is $13.1 million, with a median of $3.8 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 1,057.99% in 2024, then tumbled by 97.15% in 2025.
  • Taysha Gene Therapies' Other Non-Current Liabilities (Quarterly) stood at $4.1 million in 2022, then crashed by 61.82% to $1.6 million in 2023, then dropped by 16.99% to $1.3 million in 2024, then crashed by 96.45% to $1.6 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.6 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.2 million for Q1 2025.